Eligibility for Nirmatrelvir/Ritonavir Among Adults With an Acute Care <scp>COVID</scp> ‐19 Encounter: A Retrospective Cohort Study From Alberta, Canada
Results from this real-world study show that most adults with an acute care COVID-19 encounter who were assessed as medically eligible for NMV-r at the time of presentation had not received this outpatient treatment beforehand in Alberta, Canada, suggesting a potential care gap. If gaps are closed, strain on the acute healthcare system can be alleviated, with attendant improvement in other important patient outcomes.
Authors
- Lynora Saxinger (ORCID: https://orcid.org/0000-0003-4133-9337)
- Scott Klarenbach (ORCID: https://orcid.org/0000-0002-8611-1056)
- Jenine R. Leal (ORCID: https://orcid.org/0000-0002-0308-4890)
- Jason R. Randall (ORCID: https://orcid.org/0000-0002-0288-3551)
- Tyler Williamson (ORCID: https://orcid.org/0000-0001-5029-2345)
- Ellen Rafferty (ORCID: https://orcid.org/0000-0001-9974-8016)
- Phuong Uyen Nguyen
- Karen J. B. Martins
- Sylvia Aponte‐Hao
- Elissa Rennert‐May
- Khanh Vu
Institutions
- Alberta Health Services (CA)
- University of Alberta (CA)
- University of Calgary (CA)
- Alberta Children's Hospital (CA)
- Calgary Laboratory Services (CA)
- Institute of Health Economics (CA)
- Libin Cardiovascular Institute of Alberta (CA)
Publication Details
- Journal
- Pharmacoepidemiology and Drug Safety
- Published
- 2025-12-25
- DOI
- https://doi.org/10.1002/pds.70302
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- Government of Alberta
- University of Alberta
- Alberta Innovates
- Pfizer Canada